Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adverse Events
Biotech
Amgen's ph. 3 MariTide study will ramp up dosing to quell nausea
The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial.
Zoey Becker
Jun 24, 2025 9:59am
ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study
May 31, 2025 7:00pm
Intellia stock sinks on gene therapy patient's raised enzymes
May 29, 2025 9:15am
Pliant terminates lung disease trial due to adverse events
Mar 3, 2025 11:30am
Cargo offloads CAR-T, 50% of staff over efficacy, side effects
Jan 30, 2025 8:05am
Keros ends hypertension trial over fluid buildups around heart
Jan 15, 2025 8:25am
